Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C6 ketone di-ester is a synthetic exogenous ketone source developed by HVMN (Health Via Modern Nutrition) as a second-generation ketone supplement. It consists of a 1,3-butanediol backbone esterified with two molecules of hexanoic acid (caproic acid), a C6 medium-chain fatty acid. Upon oral ingestion, the ester is hydrolyzed by gastrointestinal lipases to release 1,3-butanediol and hexanoic acid. The 1,3-butanediol is subsequently metabolized in the liver to R-3-hydroxybutyrate (beta-hydroxybutyrate or BHB), while hexanoic acid is also ketogenic. This dual-metabolite approach is designed to rapidly and efficiently elevate blood ketone levels, inducing a state of nutritional ketosis. Compared to first-generation ketone monoesters, the C6 di-ester is intended to provide a more sustained elevation of BHB and improved palatability for use in ready-to-drink beverage matrices.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on c6 ketone di-ester.